Zheng Quan Shi Bao Wang·2025-06-09 08:52Group 1 - The CRO concept sector experienced a significant increase of 4.73%, leading the market in terms of growth, with 64 stocks rising, including Ruizhi Pharmaceutical which hit a 20% limit up [1] - Notable performers within the CRO sector included Xinghao Pharmaceutical, Shengnuo Biological, and Nuotai Biological, which saw increases of 27.29%, 17.58%, and 9.99% respectively [1] - The sector attracted a net inflow of 820 million yuan from major funds, with 38 stocks receiving net inflows, and 7 stocks exceeding 30 million yuan in net inflow [1] Group 2 - The top three stocks by net inflow rate were Ruizhi Pharmaceutical at 31.40%, Weiming Pharmaceutical at 28.87%, and Lianhua Technology at 17.48% [2] - Ruizhi Pharmaceutical led the net inflow with 248 million yuan, followed by Lianhua Technology with 189 million yuan and Kanglong Chemical with 64.87 million yuan [2] - The trading volume for Ruizhi Pharmaceutical was 247.77 million yuan with a turnover rate of 14.48% [2] Group 3 - Other notable stocks in the CRO sector included Meinuo Pharmaceutical with a 9.97% increase and a net inflow rate of 17.33%, and Weiming Pharmaceutical with a 9.99% increase and a net inflow rate of 28.87% [3][4] - The overall market sentiment for the CRO sector remains positive, as indicated by the strong performance and significant capital inflows [1][2]